The previous set of generics were indeed breadcrumbs when discussing their market potentials. I don’t think anyone seriously disputes this. A generic with brand/generic market with total sales of 40M and less is not a huge deal. However, a drug with a 400M, 700M, 1.6B market? Yeah, that’s big. Elite has multiple approvals like these now. Comparing the “old” generics to the majority of the approvals and filings of the recent 2 years or so is apples and oranges.
For SequestOx, there have been missteps on Elite’s part as well as goalpost-moving guidance from the FDA.
Isradipine is an extra, gravy, icing on the cake. Maybe it turns into a surprise double/triple, maybe not. What is most certainly happening is the approval and launch of generics with massive markets.
A company/stock “valued to have potential” and actually having potential are not always the same thing. You will see Elite demonstrate this in a positive way going forward.
News 
Market Data 
Discover 
AI
